HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma.

AbstractBACKGROUND/AIM:
No standard treatment has been established for poorly-differentiated neuroendocrine carcinomas (PDNEC). The aim of this study is to evaluate the response to the combination of three drugs.
MATERIAL AND METHODS:
We reviewed 21 PDNEC patients treated from 2008 to 2013 in two Institutions. Five patients were initially treated with epirubicin, fluorouracil and temozolomide. Because of toxicity, the regimen was modified into cisplatin, capecitabine and dacarbazine (scheme B-CLOVER regimen).
RESULTS:
Primary tumor site was: pancreas 7 (33%), lung 5 (24%), colon-rectum 5 (24%), unknown 3 (14%) and stomach 1 (5%). The response rate was 24% (0 complete response, 24% partial responses, 38% stable disease, 9% progression and 19% unassessable). The global overall survival (OS) is 13 months (range=1-29) and progression-free survival (PFS) was 6 months (range=1-11).
CONCLUSION:
The combination chemotherapy of cisplatinum, capecitabine and dacarbazine is feasible and should be considered as an option for PDNEC.
AuthorsEmilio Bajetta, Laura Catena, Pamela Biondani, Sara Pusceddu, Monica Valente, Nadia Bianco, Eugenio Novelli
JournalAnticancer research (Anticancer Res) Vol. 34 Issue 10 Pg. 5657-60 (Oct 2014) ISSN: 1791-7530 [Electronic] Greece
PMID25275070 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Cisplatin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Carcinoma, Neuroendocrine (drug therapy, mortality, pathology)
  • Cisplatin (administration & dosage)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Retrospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: